AAIC 2026 Study Shows Blood Test Predicts Alzheimer’s Risk
LONDON, United Kingdom, July 15, 2026 New research presented at the Alzheimer’s Association International Conference (AAIC) 2026 has revealed...
Neurology
Advertisement
Eisai Advances Alzheimer’s Care with LEQEMBI IQLIK Approval
TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...
HDT Bio Advances HDT-401 into Phase 1 Glioblastoma Trial
MONTREAL, Canada / SEATTLE, Washington, July 12, 2026 HDT Bio Corp. has launched a major Canadian clinical development initiative...
AB Science Prioritizes AML and ALS Programs
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
Eisai and Biogen Advance LEQEMBI SC for Alzheimer’s Disease
TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, July 12, 2026 Eisai Co., Ltd. and Biogen Inc. have announced new clinical...
Advertisements
Theranica Expands Nerivio Coverage Across U.S. Insured Population
BRIDGEWATER, New Jersey, USA / CAESAREA, Israel, July 9, 2026 Theranica has announced a major reimbursement milestone for Nerivio®,...
Viz.ai Expands AI Platform Into Neurodegenerative Disease
SAN FRANCISCO | July 9, 2026 Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has announced...
MindMaze Supports Stroke Recovery Combination Therapy Study
GENEVA, Switzerland, July 9, 2026 MindMaze Therapeutics Holding SA has announced its support for a University of Pittsburgh clinical...
Ipsen Reports Positive Phase III Dysport Migraine Results
PARIS, France, July 9, 2026 Ipsen has announced positive topline Phase III results from its BEOND clinical development program,...
Praxis and Remagine Collaborate on Ulixacaltamide
BOSTON, Mass. and AUSTIN, Texas, July 7, 2026 Praxis Precision Medicines and Remagine Labs have entered into a strategic...
Advertisement
